

Migraine - Pipeline Insight, 2021

<https://marketpublishers.com/r/M5A6E45D4256EN.html>

Date: June 2021

Pages: 60

Price: US\$ 2,500.00 (Single User License)

ID: M5A6E45D4256EN

Abstracts

This report can be delivered to the clients within 48 Hours

DelveInsight's, "Migraine - Pipeline Insight, 2021," report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Migraine pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

Global coverage

Migraine Understanding

Migraine: Overview

Migraine is a medical condition that involves severe, recurring headaches and other symptoms. Before the headache, there may be sensory changes that are known as an aura. A migraine is a type of headache with symptoms that can differ from those of non-migraine headaches. These may include unusual symptoms that can be scary, like tingling sensations, flashing lights, weird sounds, and blurred or lost vision.

There's no cure for migraine headaches. But many drugs can treat or even prevent them. Common migraine treatments include: Pain relief- Over-the-counter (OTC) drugs often work well. The main ingredients are acetaminophen, aspirin, caffeine, and ibuprofen. Triptans- These drugs balance the chemicals in brain, includes almotriptan (Axert), eletriptan (Relpax), sumatriptan (Imitrex), rizatriptan (Maxalt), and zolmitriptan

(Zomig).

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Migraine R&D. The therapies under development are focused on novel approaches for Migraine.

Migraine Emerging Drugs Chapters

This segment of the Migraine report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Migraine Emerging Drugs

Zavegepant: Biohaven Pharmaceuticals

Zavegepant (BHV-3500) is a third generation, high affinity, selective and structurally unique, small molecule CGRP receptor antagonist. The chemical properties of zavegepant make the product candidate potentially suitable for multiple routes of delivery, including nasal, subcutaneous, inhalation or oral administration.

It is currently in Phase III stage of development for Migraine and is being developed by Biohaven Pharmaceuticals.

STS-101: Satsuma Pharmaceuticals

STS101 (dihydroergotamine mesylate (DHE) nasal powder) for the acute treatment of migraine is Satsuma Pharmaceuticals' lead product candidate. Both STS101 dosage strengths were well-tolerated in the EMERGE trial, with low adverse event rates and no serious adverse events reported.

It is currently in Phase III stage of development for Migraine and is being developed by Satsuma Pharmaceuticals.

Further product details are provided in the report..

Migraine: Therapeutic Assessment

This segment of the report provides insights about the different Migraine drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Migraine

There are approx. 30+ key companies which are developing the Migraine. The companies which have their Migraine drug candidates in the most advanced stage, i.e. Phase III include, Biohaven Pharmaceuticals.

Phases

DelveInsight's report covers around 30+ products under different phases of clinical development like

Late-stage products (Phase III)

Mid-stage products (Phase II)

Early-stage products (Phase I/II and Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

Migraine pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Infusion

Intradermal

Intramuscular

Intranasal

Intravaginal

Oral

Parenteral

Subcutaneous

Topical

Molecule Type

Products have been categorized under various Molecule types such as

Vaccines

Monoclonal Antibody

Peptides

Polymer

Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Migraine: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Migraine therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Migraine drugs.

Migraine Report Insights

- Migraine Pipeline Analysis

- Therapeutic Assessment

- Unmet Needs

- Impact of Drugs

Migraine Report Assessment

- Pipeline Product Profiles

- Therapeutic Assessment

- Pipeline Assessment

- Inactive drugs assessment

- Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

- How many companies are developing Migraine drugs?

How many Migraine drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for Migraine?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Migraine therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for Migraine and their status?

What are the key designations that have been granted to the emerging drugs?

Key Players

Satsuma Pharmaceuticals

Biohaven Pharmaceuticals

Allodynic Therapeutics

Vaxxinity

AbbVie

Pulmatrix

AEON Biopharma

Eli Lilly and Company

Trevena

Xoc Pharmaceuticals

Pharmaleads

Pear Therapeutics

Key Products

STS-101

Zavegepant

ALLOD-2

UB-313

Atogepant

PUR-3100

ABP-450

LY3451838

TRV250

XC101

PL37

Contents

- Introduction
- Executive Summary
- Migraine: Overview
 - Structure
 - Mechanism of Action
- Pipeline Therapeutics
 - Comparative Analysis
- Therapeutic Assessment
 - Assessment by Product Type
 - Assessment by Stage and Product Type
 - Assessment by Route of Administration
 - Assessment by Stage and Route of Administration
 - Assessment by Molecule Type
 - Assessment by Stage and Molecule Type
- Migraine– DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
 - Migraine companies’ collaborations, Licensing, Acquisition -Deal Value Trends
- Migraine Collaboration Deals
 - Company-Company Collaborations (Licensing / Partnering) Analysis
 - Company-University Collaborations (Licensing / Partnering) Analysis
- Late Stage Products (Phase III)
 - Comparative Analysis
- Zavegepant: Biohaven Pharmaceuticals
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..
- Mid Stage Products (Phase II)
 - Comparative Analysis
- LY3451838: Eli Lilly and Company
 - Product Description
 - Research and Development
 - Product Development Activities
- Drug profiles in the detailed report..
- Early Stage Products (Phase I)
 - Comparative Analysis
- TRV250: Trevena

Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..
Preclinical and Discovery Stage Products
Comparative Analysis
PUR-3100: Pulmatrix
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report..

Inactive Products
Comparative Analysis
Migraine Key Companies
Migraine Key Products
Migraine- Unmet Needs
Migraine- Market Drivers and Barriers
Migraine- Future Perspectives and Conclusion
Migraine Analyst Views
Migraine Key Companies
Appendix

List Of Tables

LIST OF TABLES

- Table 1 Total Products for Migraine
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

List Of Figures

LIST OF FIGURES

- Figure 1 Total Products for Migraine
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

I would like to order

Product name: Migraine - Pipeline Insight, 2021

Product link: <https://marketpublishers.com/r/M5A6E45D4256EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M5A6E45D4256EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970